Biomarker-defined patient selection in WEE1 inhibitor development: lessons from Cyclin E1 amplification
Kovács R., Osei A., Kim M., et al.
Scientific publications
Evidence, published and peer-reviewed
More than 120 publications across 15+ years of WEE1 research — covering the mechanism, the biomarker, and the clinical data behind our programs.
Featured
Recently published
Featured · Clinical data
Phase 2 results: Zent-001 in Cyclin E1-positive platinum-resistant ovarian cancer
Updated safety, efficacy and biomarker findings from our expansion cohort, presented at a major medical oncology congress.
Peer-reviewed evidence is the foundation of everything we claim — and everything we build next.
Read the announcementSelected works
Selected publications
A representative selection across mechanism, translational science and clinical development.
WEE1 inhibition as an oral, non-chemotherapy strategy in platinum-resistant gynecologic cancers
Reeves S., Caputo L., et al.
Mechanistic drivers of WEE1 dependency across tumor types
Kim M., Gupta N., et al.
Translation of cell-cycle checkpoint biology into targeted therapies
Brooks D., Ward P., et al.
Cyclin E1 amplification as a predictive biomarker: from hypothesis to companion diagnostic
Osei A., Sandoval R., et al.
Selective oral WEE1 kinase inhibition: discovery and preclinical characterization of Zent-001
Kim M., Hoshino Y., et al.
For a full list of publications or to request reprints, contact our medical information team.